A group of 21 outstanding international experts in the field of Acute Myeloid Leukemia (AML) have commented on the 2010 European LeukemiaNet (ELN) recommendations for diagnosis and management of AML in adults, and provided an up-to-date version for 2017. The expert panel included many members of the AGP Global Steering Committee. The recommendations, based on recent evidence- and opinion-based clinical experiences, included: a revision of the ELN genetic categories, a proposal for a response category based on Minimal Residual Disease (MRD) status, and criteria for progressive disease. These recommendations were required in light of the therapeutic advancements of novel anti-leukemic agents and the discovery of the different families of genetic mutations within AML.
The ELN works in association with the AGP Global Steering Committee and the AGP Secretariat to provide an online educational platform for academic researchers and clinicians treating AML patients worldwide.
We will be providing more in-depth expert opinions on these seminal recommendations, so please stay posted.
The full article can be found published in Blood.